Alzheimer's disease is an irreversible, progressive disorder of the brain that progressively destroys memory and thinking skills of an individual. It is the most common cause of dementia (a continuous decline in thinking, behavioral and social skills that disrupts a person's ability to function independently) accounting for ~60–80% of cases.
DelveInsight presents a new addition to its newsletter portfolio, covering a disease that is the most common cause of dementia, Alzheimer's disease. The newsletters cover various aspects of the disease with an overlay of the disease, its pathology, and manifestations.
Through the newsletter, DelveInsight offers an analysis of Alzheimer's disease epidemiology, its patient pool, present treatment landscape, and treatment gaps.
It covers the upcoming therapies expected to launch in the coming decade, market scenario, drivers and restraints that are expected to impact the growth of the Alzheimer's disease market size, along with the ongoing clinical trials, R&D taking place in the domain, latest happenings and conferences to be held, and the support the Alzheimer's disease patients are receiving from the international organizations.
Fill up the form to gain access to our newsletter for rich insights into Alzheimer's disease.
Stay tuned for recent updates on Alzheimer's disease treatment landscape
Know more about What's covered:
- Indication overview
- Signs, symptoms, and diagnosis
- Epidemiological trends
- Treatment approaches
- Unmet needs
- Key Companies
- Market insights
- Clinical trials
- Pipeline drugs
- Collaborations and deals in the domain
- Top conferences
- R&D in the field
- Support from International organizations